QuantLogix ← ELV scorecard
📅 ELV Earnings Preview
Elevance Health, Inc.
Next report (est.)
10/19/2026
Countdown
38 days
EPS growth YoY
-16.8%
Revenue growth YoY
+2.6%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
04/22/2026 ±3.0% +0.0% over-priced
10/21/2025 ±1.9% -1.2% over-priced
07/17/2025 ±2.4% -12.2% under-priced
04/22/2025 ±4.7% +2.3% over-priced
10/17/2024 ±2.8% -10.6% under-priced
07/17/2024 ±2.1% -5.8% under-priced
04/18/2024 ±1.8% +3.2% under-priced
10/18/2023 ±3.1% +0.8% over-priced
Across these reports, options implied an average ±2.7% move vs an actual average of 4.5% — the stock stayed inside the implied band 50% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $8.00 $50.2B $1.8B
Q4 FY2025 $2.54 $49.7B $546M
Q3 FY2025 $5.32 $50.7B $1.2B
Q2 FY2025 $7.72 $49.8B $1.7B
Analyst posture
Buy / Strong Buy
19
Hold
10
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Buy · 75/100 Full scorecard →
Get alerted before every ELV report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on ELV before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Elevance Health, Inc. (ELV) reports in 38 days, with the next report estimated for 10/19/2026. Across the last 8 reports, options priced an average ±2.7% earnings move while the stock actually moved 4.5% on average — the market has been roughly fair on ELV's earnings risk. Fundamentals into the print: EPS down 16.8% year-over-year, revenue up 2.6%. QuantLogix's live 5-factor engine currently reads ELV as a buy at 75/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →